Underweight, ECOG‐PS scores ≥2, CPS <1, and rT4‐stage were independently associated with an increased mortality risk and may serve as independent prognostic indicators in patients with R/M HNSCC, who receive anti‐PD‐1 therapy. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.